Frontiers in Immunology (Apr 2021)
Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration
- Zhifeng Liu,
- Zhifeng Liu,
- Zhifeng Liu,
- Zhifeng Liu,
- Diekuo Zhang,
- Diekuo Zhang,
- Diekuo Zhang,
- Chao Liu,
- Chao Liu,
- Chao Liu,
- Guo Li,
- Guo Li,
- Guo Li,
- Huihong Chen,
- Huihong Chen,
- Huihong Chen,
- Hang Ling,
- Hang Ling,
- Hang Ling,
- Fengyu Zhang,
- Fengyu Zhang,
- Fengyu Zhang,
- Donghai Huang,
- Donghai Huang,
- Donghai Huang,
- Xingwei Wang,
- Xingwei Wang,
- Xingwei Wang,
- Yong Liu,
- Yong Liu,
- Yong Liu,
- Yong Liu,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang,
- Xin Zhang
Affiliations
- Zhifeng Liu
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Zhifeng Liu
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Zhifeng Liu
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Zhifeng Liu
- Department of Otorhinolaryngology, The First Affiliated Hospital of University of South China, Hengyang, China
- Diekuo Zhang
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Diekuo Zhang
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Diekuo Zhang
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Chao Liu
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Chao Liu
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Chao Liu
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Guo Li
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Guo Li
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Guo Li
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Huihong Chen
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Huihong Chen
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Huihong Chen
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Hang Ling
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Hang Ling
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Hang Ling
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Fengyu Zhang
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Fengyu Zhang
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Fengyu Zhang
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Donghai Huang
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Donghai Huang
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Donghai Huang
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Xingwei Wang
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Xingwei Wang
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Xingwei Wang
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Yong Liu
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Yong Liu
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Yong Liu
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Yong Liu
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China
- Xin Zhang
- Department of Otolaryngology Head and Neck Surgery, Xiangya Hospital, Central South University, Changsha, China
- Xin Zhang
- Otolaryngology Major Disease Research Key Laboratory of Hunan Province, Changsha, China
- Xin Zhang
- Clinical Research Center for Pharyngolaryngeal Diseases and Voice Disorders in Hunan Province, Xiangya Hospital, Changsha, China
- Xin Zhang
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Changsha, China
- DOI
- https://doi.org/10.3389/fimmu.2021.659184
- Journal volume & issue
-
Vol. 12
Abstract
Myeloid cells are a major heterogeneous cell population in the tumor immune microenvironment (TIME). Imbalance of myeloid response remains a major obstacle to a favorable prognosis and successful immune therapy. Therefore, we aimed to construct a risk model to evaluate the myeloid contexture, which may facilitate the prediction of prognosis and immune infiltration in patients with head and neck squamous cell carcinoma (HNSCC). In our study, six myeloid signature genes (including CCL13, CCR7, CD276, IL1B, LYVE1 and VEGFC) analyzed from 52 differentially expressed myeloid signature genes were finally pooled to establish a prognostic risk model, termed as myeloid gene score (MGS) in a training cohort and validated in a test cohort and an independent external cohort. Furthermore, based on the MGS subgroups, we were able to effectively identify patients with a poor prognosis, aggressive clinical parameters, immune cell infiltration status and immunotherapy response. Thus, MGS may serve as an effective prognostic signature and predictive indicator for immunotherapy response in patients with HNSCC.
Keywords
- tumor immune microenvironment
- myeloid cells
- head and neck squamous cell carcinoma
- prognosis
- immune infiltration
- immunotherapy
